Introduction
Choroideremia is an X-linked chorioretinal degenerative disease [1] . The causative gene, mutated in this disease, was identified as the CHM gene (also known as Rab Escort Protein 1, REP-1, NM_000390) in the 1990s [2] . Although there is currently no effective treatment for the disease, gene therapy is being explored [3] . Patients suffer night blindness, visual field defect, and visual acuity impairment. The visual dysfunction often progresses to total blindness. A definite diagnosis can be made with genetic analysis. However, it is sometimes difficult to differentiate this disease from other retinal dystrophies just based on clinical features [4] . In these settings, the CHM gene mutation screening is not a practical routine test in pa-tients with heterogeneous diseases including choroideremia, retinitis pigmentosa, cone-rod dystrophy, or other dystrophies.
Next-generation sequencing (NGS) is a genetic analysis technique that generates a large amount of DNA sequence data and enables a faster and more cost-effective sequencing of multiple genes in multiple patients than conventional sequencing [5] . We used NGS for retinal dystrophies and reported the prevalence of mutations in retinitis pigmentosa [6] . During the analysis, we additionally screened patients with other retinal dystrophies and identified a total of 2 patients with choroideremia. Herein, we describe these 2 cases and discuss the clinical relevance of comprehensive genetic analysis using NGS.
Case Reports

Case 1
A 41-year-old man was diagnosed with retinitis pigmentosa when he was 7 years old. His younger brother was also diagnosed with retinitis pigmentosa. Visual acuity was 50 cm/hand motion in both eyes. Fundus photography showed diffuse chorioretinal atrophy throughout the entire retina. Only small islands of visual field were preserved. Optical coherence tomography (OCT) scans showed abnormal thinning of the retina, especially in the outer retinal layers in both eyes. The left eye exhibited macular hole retinal detachment (MHRD; fig. 1 ). Despite the previous diagnosis of retinitis pigmentosa, fundus appearance and family history prompted a diagnosis of choroideremia. Comprehensive genetic screening using NGS was performed as previously described [6] , and a novel CHM mutation (c.1718_1719delAT, p.Y573fs) was detected. The mutation was confirmed with Sanger sequencing.
Case 2
A 22-year-old man experienced night blindness when he was 3 years old and was diagnosed with retinitis pigmentosa when he was 8 years old. Pigmentary fundus abnormality was also noted in his sister. However, the diagnosis details were unknown because the examination was performed in another institution. His visual acuity was 1.5 in both eyes, but his fundus showed chorioretinal atrophy, spreading from the posterior pole, except for the macula area, to around the equatorial fundus. Ring-shaped scotoma was detected with Goldmann perimeter. OCT scan showed loss of photoreceptors ( fig. 2 ). While the fundus appearance was atypical for choroideremia, a known CHM mutation (c.808C>T, p.R270*) [7] was detected by NGS in this case [6] . Again, the mutation was confirmed with Sanger sequencing.
Discussion
Herein, we described 2 patients with choroideremia, whose molecular diagnosis was obtained by NGS. For case 1, the diagnosis could be made with conventional sequencing, since the fundus appearance was characteristic for choroideremia. Nevertheless, direct sequencing is time-and labor-consuming for such a gene with 17 exons. Microarray-based screening can be an alternative method [8] but cannot detect novel mutations as the one detected in this case. We believe that NGS-based screening was useful in detecting the causative mutation in this particular case.
The second case clearly shows the utility of NGS. The fundus appearance was atypical for choroideremia. The family history (abnormal fundus in his sibling) suggested an autosomal-recessive inheritance trait. In this situation, it was difficult to suspect choroideremia based on clinical presentation. In fact, we included this patient in our previous study dealing with retinitis pigmentosa. Comprehensive screening using NGS allowed the detection of a known mutation, and the clinical diagnosis was revised to choroideremia [6] .
MHRD was incidentally found in the first case. The formation of macular hole (MH) in choroideremia has previously been reported [9, 10] . While the authors did not discuss its prevalence, they showed that 3 out of 30 patients with choroideremia had MH [9] . In the present case series, 1 out of 2 patients presented MHRD. In contrast, an OCT-based study on retinitis pigmentosa reported the prevalence of MH as 0.9% (3/323 patients) [11] . These data indicate that patients with choroideremia might be susceptible to MH formation. Although it is not easy to estimate the exact prevalence, MH formation should be carefully taken into consideration in patients with choroideremia.
The significance of molecular diagnosis in inherited retinal dystrophies has been limited because there has been no available treatment regardless of the causative gene. However, new therapeutic strategies are evolving such as gene replacement therapy for Leber congenital amaurosis [12] and choroideremia [3] . Recruiting patients, who could potentially benefit from the trial, will be crucial in the near future. NGS would serve as a tool to identify the candidate patients. 
